BRPI0811210A2 - Agente de formação de imagem, composição farmacêutica, métodos de preparação de um agente de formação de imagem, de formação de imagem óptica in vivo do corpo de um mamífero e de detecção, avaliação do estágio, diagnóstico, monitoração da progressão da doença ou monitoração do tratamento de câncer colorretal do corpo de um mamífero, e, kit para a preparação da composição farmacêutica. - Google Patents

Agente de formação de imagem, composição farmacêutica, métodos de preparação de um agente de formação de imagem, de formação de imagem óptica in vivo do corpo de um mamífero e de detecção, avaliação do estágio, diagnóstico, monitoração da progressão da doença ou monitoração do tratamento de câncer colorretal do corpo de um mamífero, e, kit para a preparação da composição farmacêutica.

Info

Publication number
BRPI0811210A2
BRPI0811210A2 BRPI0811210-0A2A BRPI0811210A BRPI0811210A2 BR PI0811210 A2 BRPI0811210 A2 BR PI0811210A2 BR PI0811210 A BRPI0811210 A BR PI0811210A BR PI0811210 A2 BRPI0811210 A2 BR PI0811210A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
mammalian
monitoring diagnosis
training agent
image training
Prior art date
Application number
BRPI0811210-0A2A
Other languages
English (en)
Inventor
Edvin Wilhelm Johannesen
Alan Cuthbertson
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0709441A external-priority patent/GB0709441D0/en
Priority claimed from GB0715682A external-priority patent/GB0715682D0/en
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Publication of BRPI0811210A2 publication Critical patent/BRPI0811210A2/pt
Publication of BRPI0811210B1 publication Critical patent/BRPI0811210B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4842—Monitoring progression or stage of a disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Solid State Image Pick-Up Elements (AREA)
BRPI0811210-0A 2007-05-16 2008-05-16 Agente de formação de imagem, composição farmacêutica, método de preparação de um agente de formação de imagem, e, kit para a preparação da composição farmacêutica BRPI0811210B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0709441.0 2007-05-16
GB0709441A GB0709441D0 (en) 2007-05-16 2007-05-16 Peptide imaging agents
GB0715682A GB0715682D0 (en) 2007-08-13 2007-08-13 Peptide imaging agents
GB0715682.1 2007-08-13
PCT/GB2008/001696 WO2008139207A2 (en) 2007-05-16 2008-05-16 Labelled hgf binding peptides for imaging

Publications (2)

Publication Number Publication Date
BRPI0811210A2 true BRPI0811210A2 (pt) 2014-11-11
BRPI0811210B1 BRPI0811210B1 (pt) 2021-11-09

Family

ID=39743846

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0811210-0A BRPI0811210B1 (pt) 2007-05-16 2008-05-16 Agente de formação de imagem, composição farmacêutica, método de preparação de um agente de formação de imagem, e, kit para a preparação da composição farmacêutica

Country Status (17)

Country Link
US (1) US8529874B2 (pt)
EP (1) EP2146749B1 (pt)
JP (1) JP2010526859A (pt)
KR (2) KR20150017387A (pt)
CN (1) CN101848734B (pt)
AT (1) ATE551073T1 (pt)
AU (1) AU2008249821B2 (pt)
BR (1) BRPI0811210B1 (pt)
CA (1) CA2685553C (pt)
ES (1) ES2385066T3 (pt)
IL (1) IL201778A0 (pt)
MX (1) MX2009012386A (pt)
NZ (1) NZ581160A (pt)
PL (1) PL2146749T3 (pt)
RU (2) RU2475266C2 (pt)
WO (1) WO2008139207A2 (pt)
ZA (1) ZA200908016B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100017102A (ko) * 2007-05-16 2010-02-16 지이 헬스케어 에이에스 광학 조영제
GB0718967D0 (en) 2007-09-28 2007-11-07 Ge Healthcare Ltd Peptide imaging agents
GB0918321D0 (en) 2009-10-20 2009-12-02 Ge Healthcare As Cyclic peptide synthesis
GB201010878D0 (en) 2010-06-29 2010-08-11 Ge Healthcare As Dye compositiion and dye syntheses
JP2013534557A (ja) * 2010-06-29 2013-09-05 ジーイー・ヘルスケア・アクスイェ・セルスカプ 色素組成物及び色素合成法
GB201013808D0 (en) 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
EP2625281A2 (en) * 2010-10-06 2013-08-14 EMD Millipore Corporation Cyanine compounds, conjugates and method of use
KR20140010096A (ko) 2011-03-01 2014-01-23 지이 헬쓰케어 리미티드 Ｐｅｔ 트레이서로서 방사능표지된 옥트레오테이트 유사체
GB201103696D0 (en) 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
DE102011118029A1 (de) 2011-06-20 2012-12-20 Universität Leipzig Modifizierte antibiotische Peptide mit variabler systemischer Freisetzung
GB201116733D0 (en) 2011-09-28 2011-11-09 Ge Healthcare As Peptide margin imaging agents
GB201116862D0 (en) 2011-09-30 2011-11-09 Ge Healthcare As Infusion imaging method
GB201121914D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
US10046068B2 (en) * 2013-03-15 2018-08-14 Arizona Board Of Regents On Behalf Of Arizona State University Saccharide conjugates
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
CN105111773B (zh) * 2015-08-19 2017-06-27 大连理工大学 一类氨基菁类荧光染料及其制备方法和应用
GB201804835D0 (en) * 2018-03-26 2018-05-09 Ge Healthcare As Formulation and method of preparation
CN112129736B (zh) * 2020-09-22 2022-08-02 四川大学华西医院 粘蛋白和循环肿瘤细胞的均相可视化/荧光poct检测方法
WO2022258455A1 (en) * 2021-06-07 2022-12-15 Surgvision Gmbh Stable liquid phantom for near-infrared fluorescence verification
TW202404643A (zh) 2022-04-20 2024-02-01 大陸商同宜醫藥（蘇州）有限公司 化合物及用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4749718B2 (ja) * 2002-05-10 2011-08-17 カーネギー・メロン・ユニヴァーシティ 官能基を含有するキラルインドール中間体およびそれらの蛍光シアニン染料
GB0223249D0 (en) * 2002-10-08 2002-11-13 Amersham Plc Improved imaging agents
AU2004214420A1 (en) * 2003-02-19 2004-09-02 Sicel Technologies Inc. In vivo fluorescence sensors, systems, and related methods operating in conjunction with fluorescent analytes
EP2284180B1 (en) * 2003-03-03 2015-09-09 Dyax Corp. Uses of peptides that specifically bind HGF receptor (cMET)
NO20034350D0 (no) * 2003-09-29 2003-09-29 Amersham Health As Optisk avbilding av kolorektal kreft
WO2005044923A1 (en) * 2003-10-31 2005-05-19 Ge Healthcare Limited Cyanine dye labelling reagents
US7785566B2 (en) 2003-11-06 2010-08-31 Ge Healthcare, Inc. Pharmaceutical compounds
NO20035682D0 (no) 2003-12-18 2003-12-18 Amersham Health As Optisk avbildning av ösofagkreft og Barretts ösofag
US8236283B2 (en) * 2005-01-06 2012-08-07 Ge Healthcare As Optical imaging
WO2006078914A1 (en) * 2005-01-21 2006-07-27 Washington University In St. Louis Compounds having rd targeting motifs
GB0502277D0 (en) 2005-02-04 2005-03-09 Amersham Plc Novel imaging agents
DE602006020710D1 (de) 2005-04-22 2011-04-28 Fred Hutchinson Cancer Res Foundation Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs
NO20053354D0 (no) * 2005-07-11 2005-07-11 Amersham Health As Optical imaging contrast agent.

Also Published As

Publication number Publication date
EP2146749A2 (en) 2010-01-27
ZA200908016B (en) 2012-04-25
RU2009140478A (ru) 2011-06-27
RU2473361C9 (ru) 2013-06-20
CN101848734A (zh) 2010-09-29
RU2473361C2 (ru) 2013-01-27
US8529874B2 (en) 2013-09-10
US20100150843A1 (en) 2010-06-17
IL201778A0 (en) 2010-06-16
WO2008139207A2 (en) 2008-11-20
WO2008139207A3 (en) 2009-02-26
BRPI0811210B1 (pt) 2021-11-09
NZ581160A (en) 2012-05-25
CA2685553C (en) 2017-03-28
CA2685553A1 (en) 2008-11-20
ATE551073T1 (de) 2012-04-15
KR20150017387A (ko) 2015-02-16
AU2008249821B2 (en) 2013-08-22
MX2009012386A (es) 2009-12-03
PL2146749T3 (pl) 2012-09-28
JP2010526859A (ja) 2010-08-05
RU2009140475A (ru) 2011-06-27
AU2008249821A1 (en) 2008-11-20
KR20100016543A (ko) 2010-02-12
EP2146749B1 (en) 2012-03-28
CN101848734B (zh) 2013-08-28
KR101578225B1 (ko) 2015-12-17
RU2475266C2 (ru) 2013-02-20
ES2385066T3 (es) 2012-07-17

Similar Documents

Publication Publication Date Title
ZA200908016B (en) Labelled hgf binding peptides for imaging
GB0718967D0 (en) Peptide imaging agents
BRPI0814339A2 (pt) composição farmacêutica, kit para a preparação da composição farmacêutica, conjugado, e, métodos de formação de imagem óptica in vivo do corpo de mamíferos, e de detecção, estabilização, diagnóstico, monitoramento do progresso da doença ou monitoramento do tratamento de um estado doentio do corpon dos mamíferos
WO2009085216A3 (en) Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
TN2014000454A1 (en) Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
EP2987807A3 (en) Antibodies recognising phospho-tau
BR112019024717A2 (pt) nanopartículas ultrapequenas marcadas com zircônio-89 e métodos das mesmas
BRPI0811588A2 (pt) Agente de formação de imagem, composição farmacêutica, kit para a preparação da mesma, conjugado, corante de cianina, e, métodos de formação de imagem óptica in vivo do corpo de um mamífero e de detecção, avaliação do estágio, diagnóstico, monitoração da progressão da doença ou monitoração do tratamento de um estado de doença do corpo de um mamífero
EP2687235A3 (en) Methods for production and use of substance-loaded erythrocytes (S-LES) for observation and treatment of microvascular hemodynamics
WO2014153160A3 (en) METHOD OF ENHANCING THE BIODISTRIBUTION AND TISSUE TARGETING PROPERTIES OF THERAPEUTIC CeO2 PARTICLES VIA NANO-ENCAPSULATION AND COATING
WO2006050058A3 (en) Methods of detection and therapy of inflamed tissues using immune modulation
WO2009126306A8 (en) Compositions and methods for detecting egfr mutations in cancer
WO2011066521A3 (en) Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
WO2009103741A3 (en) Use of fsh receptor ligands for diagnosis and therapy of cancer
WO2006090389A3 (en) Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
WO2020077341A8 (en) Methods and compositions for identifying and treating subjects at risk for poor car t cell therapy response
WO2004100998A3 (en) Compositions and methods for non-invasive imaging of soluble beta-amyloid
WO2010051196A8 (en) Novel substituted azabenzoxazoles
WO2004104591A3 (en) Improvements to gamma delta t cell-mediated therapy
WO2005113831A3 (en) Biomarkers for multiple sclerosis and methods of use thereof
WO2009109569A3 (en) Ester imaging agents
WO2009016231A3 (en) Compositions and methods for detecting histamine related disorders
CN103998929A (zh) 选择患者的方法
EP3212239A1 (en) Quinoline-3-carboxamide compounds and their use in diagnosis
WO2011073905A8 (en) Novel tumor markers

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 49/00 (2006.01), A61B 5/00 (2006.01)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/05/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: RETIFICA-SE O DEFERIMENTO NOTIFICADO NA RPI NO 2636 DE 13/07/2021.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2827 DE 11-03-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.